Screener
McKesson MCK Prescription Technology Solutions — Non-cash charges
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by McKesson in its filing.
Tagged under the XBRL concept us-gaap:RestructuringReserveSettledWithoutCash2.
The source filing: McKesson’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:29 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000927653-26-000234
| (In millions) | North American Pharmaceutical | Prescription Technology Solutions | Medical-Surgical Solutions | Corporate | Total |
|---|---|---|---|---|---|
| Balance, March 31, 2026 (1) | $18 | $3 | $10 | $13 | $44 |
| Restructuring, impairment, and related charges, net | 2 | 61 | 23 | 50 | 136 |
| Non-cash charges | (1) | (40) | — | (6) | (47) |
| Cash payments | (3) | — | (16) | (40) | (59) |
| Balance, June 30, 2026 (2) | $16 | $24 | $17 | $17 | $74 |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is McKesson's prescription technology solutions — non-cash charges?
- McKesson (MCK) reported prescription technology solutions — non-cash charges of $40M in Q2 2026.
- What does prescription technology solutions — non-cash charges mean?
- Captures expenses recognized in the income statement that do not involve an immediate cash outflow, specifically within the Prescription Technology Solutions segment. This includes items like depreciation, amortization, and stock-based compensation that impact reported earnings.
Ask your AI about McKesson's prescription technology solutions — non-cash charges.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude